LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Novavax Inc

Closed

SectorHealthcare

6.72 7.35

Overview

Share price change

24h

Current

Min

6.29

Max

6.88

Key metrics

By Trading Economics

Income

600M

519M

Sales

578M

667M

EPS

2.93

Profit margin

77.798

Employees

952

EBITDA

569M

516M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+114.77% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

11M

1B

Previous open

-0.63

Previous close

6.72

News Sentiment

By Acuity

18%

82%

29 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Novavax Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 kwi 2025, 17:06 UTC

Major Market Movers

Novavax Falls But Then Recovers After WSJ Report on Vaccine's FDA Status

31 mar 2025, 14:19 UTC

Major Market Movers

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

4 lut 2025, 18:52 UTC

Major Market Movers

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

11 lis 2024, 14:05 UTC

Major Market Movers

Novavax to Move Forward With Covid-19, Influenza Vaccine After FDA Lifts Clinical Hold

16 paź 2024, 12:59 UTC

Major Market Movers

Novavax Says FDA Puts Clinical Hold on Covid-19, Flu Vaccines; Shares Drop

8 maj 2025, 17:55 UTC

Earnings

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

8 maj 2025, 15:12 UTC

Earnings

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

28 kwi 2025, 17:04 UTC

Earnings

Novavax Stock Is Up Again. There Are Still Big Questions About the Fate of Its Covid Shot. -- Barrons.com

30 gru 2024, 23:02 UTC

Acquisitions, Mergers, Takeovers

Novavax Completes Previously Announced $200M Sale of Czech Republic Manufacturing Site to Novo Nordisk

4 gru 2024, 07:09 UTC

Acquisitions, Mergers, Takeovers

Novavax: Agreement to Close by Dec 30 >NVAX

4 gru 2024, 07:08 UTC

Acquisitions, Mergers, Takeovers

Novavax: Sale Aligns With Plan to Become More Lean Organization, Drive Value From Pipeline Assets & Tech Platform >NVAX

4 gru 2024, 07:07 UTC

Acquisitions, Mergers, Takeovers

Novavax: Deal to Also Reduce Annual Operating Costs by About $80M >NVAX

4 gru 2024, 07:06 UTC

Acquisitions, Mergers, Takeovers

Novavax to Get $190M Cash Payment in 2024, Additional $10M in 2025 >NVAX

4 gru 2024, 07:06 UTC

Acquisitions, Mergers, Takeovers

Novavax: Agreement Provides Company With Significant, Non-Dilutive Capital >NVAX

4 gru 2024, 07:04 UTC

Acquisitions, Mergers, Takeovers

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200M

15 lis 2024, 13:34 UTC

Top News

Heard on the Street: RFK Jr. Is Spooking Obesity Investors Too -- WSJ

15 lis 2024, 11:14 UTC

Market Talk

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

16 paź 2024, 15:22 UTC

Earnings

These Stocks Are Moving the Most Today: ASML, Nvidia, Morgan Stanley, United Airlines, DJT, Novavax, J.B. Hunt, Cisco, and More -- Barrons.com

Peer Comparison

Price change

Novavax Inc Forecast

Price Target

By TipRanks

114.77% upside

12 Months Forecast

Average 12.8 USD  114.77%

High 19 USD

Low 7 USD

Based on 5 Wall Street analysts offering 12 month price targets forNovavax Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

2

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

5.692 / 6.039Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

29 / 382 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.